The Vaccine Company
Part of Eli Lilly and Company
Organization
Trials
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Phase 1, Completed, 130 people, Jul 10, 2023
Phase 2, Status unknown, 30 people, Aug 8, 2007
Phase 3, Status unknown, 244 people, Mar 30, 2007
Collaborator, Phase 2, Terminated, 5 people, Dec 25, 2006
Sources: clinicaltrials.gov
Named in competing interests
Grants or research support, Jan 10, 2025
Grants or research support, Apr 17, 2024
Sources: pubmed.ncbi.nlm.nih.gov